logo
  

Clearside Reports Positive Safety Results From OASIS Phase 1/2a Trial Of CLS-AX - Quick Facts

Clearside Biomedical, Inc. (CLSD) reported positive safety results from OASIS, an ongoing phase 1/2a clinical trial of CLS-AX administered by suprachoroidal injection via SCS Microinjector. The company said the data reported includes results from Cohort 2 as well as combined data from Cohorts 1 and 2. The primary endpoints were achieved in Cohort 2, as the 0.1 mg dose of CLS-AX was well tolerated with no serious adverse events. The OASIS Safety Monitoring Committee has approved advancing to Cohort 3 with a dose of 0.5 mg of CLS-AX.

"We believe the absence of any dose limiting toxicities in the first two cohorts of the OASIS trial, combined with our pre-clinical toxicology data, supports our plan to escalate to the higher CLS-AX dose of 0.5 mg in Cohort 3 rather than the previous 0.3 mg dose. We have initiated patient screening for Cohort 3, with target completion of this cohort planned for mid-year 2022," said Thomas Ciulla, Chief Medical Officer.

OASIS is evaluating CLS-AX for the treatment of neovascular age-related macular degeneration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission or FTC, has sued Walmart for allowing its money transfer services to be used by fraudsters, who fleeced consumers out of hundreds of millions of dollars. The retail giant is alleged to have looked the other way to pocket millions in fees while scammers took advantage of its failure to properly secure the money transfer services offered at Walmart stores. Home improvement retailer Bed Bath & Beyond, Inc. (BBBY) reported on Wednesday a net loss for first quarter that sharply widened from last year, hurt by hefty transient costs related to inventory markdown reserves and port-related supply chain fees. Both adjusted loss per share and net sales missed analysts' expectations. Tesla Inc. laid off about 200 employees in its Autopilot unit as the luxury electric car maker closed down its office in San Mateo, California as part of cost cutting efforts, reports said. The San Mateo office, where employees worked on improving the driver assistance systems, marketed as Autopilot, had about 350 employees before the cut.
Follow RTT